Cellect Biomed registers $10.81 million of stock for public ADS sale

American Depositary Shares sold by Rodman & Renshaw, Chardan Capital

By Devika Patel

Knoxville, Tenn., July 7 – Cellect Biomed Ltd. will sell American Depositary Shares in a public sale with a greenshoe, according to a Form F-1 filed Thursday with the Securities and Exchange Commission. The company has registered up to $10.81 million of underlying ordinary stock for the deal.

Rodman & Renshaw is the bookrunner. Chardan Capital Markets, LLC is the co-manager.

Proceeds will be used for clinical trials, development, general research activities, working capital and general corporate purposes, including establishing an office in the United States.

The biotechnology company is based in Kfar Saba, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.